|
1) Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005; 60: 1025-30
|
|
|
|
2) Provencher S, Sitbon O, Humbaert M, et al. Long-term outocome with first-line bosentan thearapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27: 589-95
|
|
|
|
|
|
3) Steiner MK, Preston IR, Klinger JR, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension. Chest. 2006; 130: 1471-80
|
|
|
|
|
|
4) Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J. 2005; 69: 131-7
|
|
|
|
|
5) Blackt SM, Mata-Greenwood E, Dettman RW, et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation. 2003; 108: 1646-54
|
|
|
|
|
|
6) Christensen DD, McConnell ME, Book WM, et al. Initial experience with bosentan therapy in patietns with Eisenmenger syndrome. Am J Cardiol. 2004; 94: 261-3
|
|
|
|
|
|
7) Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome. Circulation. 2006; 114: 48-54
|
|
|
|
|
|
8) Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in padiatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003; 73: 372-82
|
|
|
|
|
|
9) Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with Bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2006; 25: 469-73
|
|
|
|
|
|
10) Keogh AM, McNeil KD, Wlodarcyk J, et al. Quality of life in pulmonary arterial hypertension: Improvement and maintenanance with Bosentan. J Heart Lung Transplant. 2007; 26: 181-7
|
|
|
|
|
|
11) Gilbert N, Luther Y-C, Miera O, et al. Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. Z Kardiol. 2005; 94: 570-4
|
|
|
|
|
|
12) Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan therapy in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart. 2007; 93: 350-4
|
|
|
|
|
|
13) Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006; 65: 1336-40
|
|
|
|
|
|
14) Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest. 2006; 36 Suppl 3: 54-61
|
|
|
|
|
|
15) Baltogiannis GG, Tsalikakis DG, Mitsi AC, et al. Endothelin receptor-a blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovascu Res. 2005; 67: 647-54
|
|
|
|
|
|
16) Maiya S, Hislop AA, Lynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart. 2006; 92: 664-70
|
|
|
|
|
|
17) Steiner MK, Preston IR, Klinger JR, et al. Conversion to Bosentan from Prostacyclin infusion therapy in pulmonary arterial hypertension. Chest. 2006; 130: 1471-80
|
|
|
|
|
|
18) Camacho AF, Subias PE, Tello de Meneses R, et al. Transition from prostacyclin to bosentan in five patients with severe pulmonary hypertension: the switch is possible. Rev Esp Cardiol. 2006; 59: 737-9
|
|
|
|
|
|
19) McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to exsisting bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174: 1257-63
|
|
|
|
|
|
20) Channick RN, Olschewski H, Seeger W, et al. Safety and Efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006; 48: 1433-7
|
|
|
|
|
|
21) Seyfarth HJ, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest. 2005; 128: 709-13
|
|
|
|
|
|
22) Paul GA, Gibbs JSR, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005; 60: 107-12
|
|
|
|
|
|
23) Givert MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000; 101: 2922-7
|
|
|
|
|
|
24) Apostolopoulou SC, Rammos S, Kyriakides ZS, et al. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart. 2003; 89: 1221-6
|
|
|
|
|
|
25) Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonists, in patients with pulmonary hypertension. Circulation. 2000; 102: 411-8
|
|
|
|
|
|
26) Suntharalingam J, Hodgkins D, Cafferty FH, et al. Does rapid dose titration affect the hepatic safety profile of Bosentan？ Vascul Pharmacol. 2006; 44: 508-12
|
|
|
|
|
|
27) Barst RJ, Rich S, Widlitz A, et al. Clinical Efficacy of Sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest. 2002; 121: 1860-8
|
|
|
|
|
|
28) Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with selective endothelin-A receptor antagonist Sitaxsentan. J Am Coll Cardiol. 2006; 47: 2049-56
|
|
|
|
|
|
29) Horn EM, Widlitz AC, Barst RJ. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs. 2004; 13: 1483-92
|
|
|
|
|
|
30) Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169: 441-7
|
|
|
|
|
|
31) Langleben D, Hirsh AM, Shalit E, et al. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, Sitaxsentan, in patients with pulmonary arterial hypertension. Chest. 2004; 126: 1377-81
|
|
|
|
|
|
32) Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46: 529-35
|
|
|
|
|
|
33) Abman SH. Pulmonary hypertension in older children: New approaches and therapies. Ped Respiratory Rev. 2006; 7S: S177-9
|
|
|
|
|
|
34) Billman GE, Ambrisentan (Myogen). Curr Opin Invest Drugs. 2002; 3: 1483-6
|
|
|
|
|
|
35) Rubin LJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol. 2005; 1: 425-32
|
|
|
|
|
|
36) Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochran Database Syst Rev. 2006; 3: CD004434
|
|
|
|
|